jayempi
nova laboratories ireland limited - azathioprine - odmítnutí štěpu - imunosupresiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
methoxasol 20/100 mg/ml roztok pro podání v pitné vodě
eurovet animal health, b.v. - sulfamethoxazol a trimethoprime - roztok pro podání v pitné vodě - kombinace sulfonamidů a trimethoprimu, včetně. deriváty - prasata, brojleři kura domácího
kerendia
bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - agens působící na systém renin-angiotenzin - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
xydalba
abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibakteriální látky pro systémové použití, - léčba akutních bakteriálních infekcí kůže a struktury kůže (absssi) u dospělých.
xenleta
nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibakteriální látky pro systémové použití, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. pozornost by měla být věnována oficiálním doporučením pro správné používání antibakteriálních látek.
imasup 25mg potahovaná tableta
bausch health ireland limited, dublin array - 1709 azathioprin - potahovaná tableta - 25mg - azathioprin
imasup 50mg potahovaná tableta
bausch health ireland limited, dublin array - 1709 azathioprin - potahovaná tableta - 50mg - azathioprin
imuran 25mg potahovaná tableta
aspen pharma trading limited, dublin array - 1709 azathioprin - potahovaná tableta - 25mg - azathioprin
imuran 50mg potahovaná tableta
aspen pharma trading limited, dublin array - 1709 azathioprin - potahovaná tableta - 50mg - azathioprin
midazolam hameln 1mg/ml injekční/infuzní roztok
hameln pharma gmbh, hameln array - 5535 midazolam-hydrochlorid - injekční/infuzní roztok - 1mg/ml - midazolam